ESPE Abstracts

Introduction: The EOSS is a clinical tool to assess the burden of obesity and has been shown in adults to predict later morbidity and mortality. We found that the pediatric version (EOSS-P) appears to predict later cardiometabolic outcomes, however whether it is a better predictor than anthropometrics alone remains unclear.Objectives: To compare associations between EOSS-P stage at 8-10 years and cardiometabolic outcomes...

Introduction: Pediatric obesity is is increasing worldwide. Children and adolescents affected are at increased risk of Type 2 Diabetes Mellitus and its cardiovascular complications, starting in young adulthood and linked to insulin resistance and its inflammatory milieu. The SPISE index, calculated using baseline triglycerides, HDL cholesterol, and BMI, shows promise in predicting insulin resistance in this population. It is not affected by insulin secretion p...

Background: Bardet-Biedl syndrome (BBS) is a rare autosomal recessive inherited ciliopathy with pathogenic variants in at least 26 BBS genes. It affects multiple organs including kidney and liver; however, organ involvement differs widely regarding extent and time of first manifestation. Structural renal anomalies are an early feature with a frequency of > 50% and end-stage kidney disease (ESKD) cumulates to 25% in adolescence. Early-onset hyperphagia-assoc...

Background/Objectives: Blood amino acid (AA) and acylcarnitine (AC) concentrations are informative on physiological and disease-associated changes in human metabolic pathways. Previously, AAs and ACs were examined as potential biomarkers or predictors of complex metabolic diseases in adults and children. However, there is still a lack of studies examining physiological AA and AC blood levels in healthy paediatric populations. We aimed to assess the intra-perso...

Background and aim: Fibroblast growth factor 21 (FGF21) is produced and expressed in several tissues but mainly in the liver and adipose tissue, where it has endocrine and paracrine functions. Several experimental studies reported that FGF21 decreases lipogenesis, triggers beta oxidation of fatty acids, reduces hepatic ER stress and VLDL release and reduces fasting and postprandial triacylglycerols (TG). Consistently, several phase 2 trials with FGF21-agonists...

Background and aim: Pediatric patients with germline mutations in phosphatase and tensin homolog (Pten) frequently develop aberrant adipose tissue growth/lipomas. In severe cases this can have adverse effects on organ function and quality of life. Due to the lack of understanding the basis of lipoma development, no systemic treatment options are available. We therefore aimed to characterize an already described lipoma bearing mouse model with conditio...